The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. Feel unsure about the ...

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

Leading molecular glues companies, such as Bristol Myers Squibb, Salarius Pharmaceuticals, Nested Therapeutics, Monte Rosa Therapeutics, and others, are developing novel molecular glues that can ...

However, companies and research organizations focused on molecular glue drug discovery are developing pipelines of therapeutics that are moving toward clinical evaluation. The rational design ...

Leading molecular glues companies, such as Bristol Myers Squibb, Salarius Pharmaceuticals, Nested Therapeutics, Monte Rosa Therapeutics, and others, are developing novel molecular glues that can ...

Leading molecular glues companies, such as Bristol Myers Squibb, Salarius Pharmaceuticals, Nested Therapeutics, Monte Rosa Therapeutics, and others, are developing novel molecular glues that can be ...